Form 4: FRACTYL HEALTH, INC.: Officer Kieffer Timothy Reports Stock Option Grant
SEC Form 4
Chief Scientific Officer Timothy Kieffer reports the acquisition of stock options in FRACTYL HEALTH, INC.
Summary
- On February 27, 2025, Timothy Kieffer, Chief Scientific Officer of FRACTYL HEALTH, INC., reported the acquisition of stock options.
- Kieffer acquired options to purchase 169,700 shares at an exercise price of $1.46, vesting in equal installments over four years from the grant date, and options to purchase 35,280 shares at an exercise price of $15, vesting over three years.
- The options are directly owned by Kieffer.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The option grants suggest confidence in the company's future, but it's not overtly positive or negative.
Positives
- The grant of stock options to a key officer like the Chief Scientific Officer suggests an incentive alignment with the company's long-term performance.
- The vesting schedules encourage continued employment and achievement of performance goals.
Future Outlook
The vesting schedules of the stock options indicate a multi-year commitment from the Chief Scientific Officer.
Industry Context
Stock option grants are a common form of executive compensation in the biotech and pharmaceutical industries, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the healthcare industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
- The vesting schedules and exercise prices are generally aligned with industry norms to retain key personnel and drive long-term value creation.
Stakeholder Impact
- Shareholders may view the stock option grants as a positive sign, aligning management's interests with the company's success.
- Employees may see this as a positive sign of investment in key personnel.
Key Dates
| Date | Description |
|---|---|
| 02/01/2024 | Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 58,800 shares of common stock in connection with the Issuer's initial public offering |
| 12/31/2024 | 25% of the 35,280 performance based options vested |
| 02/27/2025 | Date of transaction: Timothy Kieffer acquired stock options. |
| 03/03/2025 | Date of filing. |
| 02/26/2035 | Expiration date for 169,700 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.